Background Osteoporosis results in reduced bone mass and consequent bone fragility.
Small interfering RNAs (siRNAs) can be used for therapeutic purposes, as molecular targets …

Hip fractures are a leading cause of hospitalisation in elderly patients, representing an
increasing socioeconomic problem arising from demographic changes, considering the …

Osteoporotic fractures, also known as fragility fractures, are prevalent in the elderly and
bring tremendous social burdens. Poor bone quality, weak repair capacity, instability, and …

Osteoporosis affects more than 200 million women worldwide, with postmenopausal women
being particularly susceptible to this condition and its severe sequelae disproportionately …

Background Osteoporosis (OP), often referred to as the “silent disease of the twenty-first
century,” poses a significant public health concern due to its severity, chronic nature, and …

Background Osteoporosis is a prevalent comorbidity in patients with COPD that is usually
underrecognized and hence, undertreated. Compared to the gold standard dual-energy X …

Introduction Pharmacological strategies might influence bone healing in terms of time to
union or quality of mature bone. This expert opinion discussed the current level I evidence …

Purpose To explore the value of vertebral bone quality (VBQ) scores in diagnosing
osteoporosis in patients with lumbar degeneration. Methods A retrospective analysis was …

Abstract Background Liuwei Dihuang Pill (LP) was verified to alleviate postmenopausal
osteoporosis (PMOP) development. Nevertheless, the major constituent of LP and the …

Objective Secoisolariciresinol diglucoside (SDG) is a phytoestrogen that has been reported
to improve postmenopausal osteoporosis (PMOP) caused by estrogen deficiency. In our …